VanEck Biotech ETF (BBH)

NASDAQ: BBH · Real-Time Price · USD
181.78
-4.21 (-2.27%)
At close: May 15, 2026, 4:00 PM EDT
182.00
+0.22 (0.12%)
After-hours: May 15, 2026, 4:15 PM EDT
Assets$362.06M
Expense Ratio0.35%
PE Ratio22.52
Shares Out1.95M
Dividend (ttm)$0.96
Dividend Yield0.53%
Ex-Dividend DateDec 22, 2025
Payout FrequencyAnnual
Payout Ratio11.50%
Volume8,204
Open185.06
Previous Close185.99
Day's Range181.74 - 185.06
52-Week Low140.17
52-Week High202.91
Beta0.72
Holdings25
Inception DateDec 20, 2011

About BBH

Fund Home Page

The VanEck Biotech ETF (BBH) is an exchange-traded fund that is based on the MVIS US Listed Biotech 25 index, a market-cap-weighted index of the 25 largest biotech firms globally. BBH was launched on Dec 20, 2011 and is issued by VanEck.

Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol BBH
ETF Provider VanEck
Index Tracked MVIS US Listed Biotech 25

Top 10 Holdings

69.72% of assets
NameSymbolWeight
Amgen Inc.AMGN14.05%
Gilead Sciences, Inc.GILD14.02%
Vertex Pharmaceuticals IncorporatedVRTX8.22%
Regeneron Pharmaceuticals, Inc.REGN7.01%
argenx SEARGX6.01%
Revolution Medicines, Inc.RVMD4.45%
IQVIA Holdings Inc.IQV4.35%
Natera, Inc.NTRA3.96%
Biogen Inc.BIIB3.93%
United Therapeutics CorporationUTHR3.74%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Dec 22, 2025$0.9565Dec 26, 2025
Dec 23, 2024$1.2517Dec 24, 2024
Dec 18, 2023$0.7127Dec 22, 2023
Dec 19, 2022$0.7488Dec 23, 2022
Dec 20, 2021$0.3972Dec 27, 2021
Dec 21, 2020$0.6079Dec 28, 2020
Full Dividend History

Performance

BBH had a total return of 30.26% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.58%.

News

VanEck Announces Year-End Distributions for VanEck Equity ETFs

NEW YORK--(BUSINESS WIRE)--VanEck announced today the 2025 annual distributions per share for its VanEck equity exchange-traded funds.

5 months ago - Business Wire

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

Other symbols: ARGXBMRNCYTKIBBXBI
9 months ago - CNBC Television

ETF Investors Indicate Active Strategies and Product Innovation Will Fuel the Industry's Continued Growth: BBH 2024 Global ETF Investor Survey

BOSTON--(BUSINESS WIRE)--As the ETF industry reaches a milestone of $12.71 trillion in global assets, the Brown Brothers Harriman 2024 Global ETF Investor Survey finds that investors plan to further i...

2 years ago - Business Wire

Brown Brothers Harriman Private Banking Team Expands in Philadelphia

PHILADELPHIA--(BUSINESS WIRE)--The Private Banking arm of Brown Brothers Harriman & Co. (BBH) is pleased to announce the expansion and strengthening of its Corporate Advisory and Banking team in Phi...

3 years ago - Business Wire

VanEck Announces Yearend Distributions for VanEck Equity ETFs

NEW YORK--(BUSINESS WIRE)--VanEck announced today the following 2022 annual distributions per share for its VanEck® equity exchange-traded funds.

3 years ago - Business Wire

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

5 years ago - Kiplinger

Biotech ETFs at multi-week highs, extending winning streak

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...

Other symbols: FBTIBBXBI
6 years ago - Market Watch

Coronavirus treatment: FDA authorizes convalescent plasma for COVID-19 use

Yahoo Finance's Anjalee Khemlani reports on the FDA's approval on the use of convalescent plasma to treat COVID-19.

Other symbols: IBBXBI
6 years ago - Yahoo Finance